Clascoterone (Cortexolone 17 alpha-propionate;Cortexolone 17α-propionate;CB-03-01) is the active ingredient in a new selective androgenic inhibitor: basically topical finasteride without the systemic effects because of it’s selective receptor nature as I understand. It’s going under the name “breezula”, it has passed phase 2 trials with good results and expected to release 2021/2022:
Clascoterone (Cortexolone 17 alpha-propionate) | Androgen Receptor Antagonist | MedChemExpress
Clascoterone (Cortexolone 17 alpha-propionate) | Androgen Receptor Antagonist | MedChemExpress